● Recruiting

Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy

Condition: Breast Cancer · Sponsor: The First Affiliated Hospital with Nanjing Medical University

PhasePhase 2

Planned participants150

Who can joinFemale, 30 Years to 75 Years

Healthy volunteersNo

About this study

This study is a multicenter, single-arm, phase II clinical trial, aiming to evaluate the safety and efficacy of tumor bed dose escalation radiotherapy for patients with primary breast lesions achieving pCR (ypT0) after neoadjuvant chemotherapy and breast-conserving surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Xinchen Sun, Doctor · 13770662828 · 13770662828@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated with Nanjing Medical University (Jiangsu Province People's Hospital)

Nanjing, Jiangsu, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07113613